Zamarripa C Austin, Novak Matthew D, Weerts Elise M, Vandrey Ryan, Spindle Tory R
Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Front Pharmacol. 2022 Sep 6;13:964749. doi: 10.3389/fphar.2022.964749. eCollection 2022.
The legalization of cannabis for medicinal and non-medicinal purposes, and the corresponding increase in diversity of cannabis products, has resulted an urgent need for cannabis regulatory science. Among the most pressing needs is research related to impairment due to cannabis exposure, especially on driving performance. The present project was designed to evaluate the impact of oral and vaporized cannabis, when administered alone or in combination with alcohol, on simulated driving performance (STISIM driving simulator), cognitive/psychomotor ability, and field sobriety performance. Healthy adults will complete two, double-blind, double-dummy, placebo-controlled, randomized crossover clinical laboratory studies, one with oral cannabis (16 men/16 women) and the second with vaporized cannabis (16 men/16 women). In each study, participants will complete seven experimental sessions during which acute doses of placebo or high Δ9-THC cannabis containing 0, 10, or 25 mg Δ9-THC will be administered both alone and in combination with placebo or alcohol-containing beverages (target breath alcohol concentrations, BAC, of 0.0% or 0.05%). A positive control session (i.e., alcohol at target BAC of 0.08% with placebo cannabis) will also be completed. Simulated driving performance tests (available for download; see Methods), field sobriety assessments, subjective drug effect questionnaires, a mobile device impairment test (DRUID app), and collection of whole blood specimens will be completed repeatedly during each session. Linear mixed models will be used to test for differences across experimental conditions and planned comparisons will be used to determine differences between conditions of interest (e.g., cannabis alone vs cannabis with alcohol). This research is designed to extend prior studies of cannabis and alcohol on driving performance by using oral and vaporized routes of cannabis administration. By increasing understanding of impairment associated with co-use of alcohol and these novel forms of cannabis, this research could inform impairment detection standards for cannabis and alcohol and have important implications for law enforcement, public policy decisions regarding accessibility of these substances, and education of the general population who may use cannabis and/or alcohol. Lastly, this manuscript provides interested researchers with access to the simulated driving scenarios and data extraction tools developed for this study as a means of facilitating future cross-study comparisons, which is important given the heterogeneity in methods used across laboratories in prior research.
大麻用于医疗和非医疗目的的合法化,以及相应的大麻产品多样性增加,导致了对大麻监管科学的迫切需求。最紧迫的需求之一是与大麻暴露导致的损害相关的研究,尤其是对驾驶性能的影响。本项目旨在评估口服和雾化大麻单独使用或与酒精联合使用时,对模拟驾驶性能(STISIM驾驶模拟器)、认知/心理运动能力和现场清醒度表现的影响。健康成年人将完成两项双盲、双模拟、安慰剂对照、随机交叉临床实验室研究,一项使用口服大麻(16名男性/16名女性),另一项使用雾化大麻(16名男性/16名女性)。在每项研究中,参与者将完成七个实验环节,在此期间,将单独以及与安慰剂或含酒精饮料联合给予急性剂量的安慰剂或含高Δ9-四氢大麻酚(Δ9-THC)的大麻(含0、10或25毫克Δ9-THC)。还将完成一个阳性对照环节(即目标呼气酒精浓度(BAC)为0.08%的酒精与安慰剂大麻)。在每个环节中,将反复完成模拟驾驶性能测试(可下载;见方法)、现场清醒度评估、主观药物效果问卷、移动设备损伤测试(DRUID应用程序)以及采集全血样本。将使用线性混合模型来测试不同实验条件之间的差异,并将使用计划比较来确定感兴趣条件之间的差异(例如,单独使用大麻与大麻与酒精联合使用)。本研究旨在通过使用口服和雾化大麻给药途径,扩展先前关于大麻和酒精对驾驶性能影响的研究。通过增进对与酒精和这些新型大麻共同使用相关损害的理解,本研究可为大麻和酒精的损害检测标准提供信息,并对执法、关于这些物质可及性的公共政策决策以及对可能使用大麻和/或酒精的普通人群的教育产生重要影响。最后,本手稿为感兴趣的研究人员提供了访问为本研究开发的模拟驾驶场景和数据提取工具的途径,作为促进未来跨研究比较的一种手段,鉴于先前研究中各实验室使用方法的异质性,这一点很重要。